Compounds, compositions and methods of use for nicotine cessation and chemoprevention

Abstract

Compounds, compositions, and methods of use of such compounds and compositions are provided for reducing human dependency to nicotine. In one example, a method of treating an individual with an addiction to nicotine comprises administering to the individual a compound that is a structural analog of trans-cinnamaldehyde. Based on the administration, a rate at which nicotine is metabolized may be reduced, which in turn may reduce a desire for the individual to consume nicotine-containing products.

1 - 10 . (canceled) 
     
     
         11 . A pharmaceutical composition for reducing a rate at which nicotine is metabolized comprising one of the following compounds: 
       
         
           
           
               
               
           
         
         wherein the rate is reduced based on the pharmaceutical composition inhibiting an enzyme that metabolizes nicotine in a time-dependent manner. 
       
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein R is one of chlorine, bromine, and an alkyl group. 
     
     
         13 . The pharmaceutical composition of  claim 11 , wherein R1 is a halogen, a nitro group, a trifluoromethyl group, a trichloromethyl group, or a methoxy group. 
     
     
         14 . The pharmaceutical composition of  claim 11 , further comprising an oil. 
     
     
         15 . The pharmaceutical composition of  claim 11 , further comprising a surfactant. 
     
     
         16 . The pharmaceutical composition of  claim 11 , further comprising a co-surfactant. 
     
     
         17 . A compound for reducing a rate of nicotine metabolism, the compound of the following chemical structure: 
       
         
           
           
               
               
           
         
         wherein R1 is an electron-withdrawing group, and wherein R is a straight chain or a branched chain alkyl group. 
       
     
     
         18 . The compound of  claim 17 , wherein the electron withdrawing group is a nitro group, and wherein the alkyl group is a methyl group. 
     
     
         19 . The compound of  claim 18 , wherein R1 is at an ortho position of the compound. 
     
     
         20 . The compound of  claim 17 , wherein the compound inhibits cytochrome p450 2A6 (CYP2A6) and/or CYP2A13.